Hoffmann, Christian, Schmid, Holger, Mueller, Markus, Teutsch, Christian, van Lunzen, Jan, Esser, Stefan, Wolf, Timo, Wyen, Christoph, Sabranski, Michael, Horst, Heinz-August, Reuter, Stefan, Vogel, Martin, Jaeger, Hans, Bogner, Johannes and Arasteh, Keikawus (2011). Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood, 118 (13). S. 3499 - 3504. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Full text not available from this repository.

Abstract

Although HIV-associated multicentric Castleman disease (HIV-MCD) is not classified as an AIDS-defining illness, mortality is high and progression to lymphoma occurs frequently. At present, there is no widely accepted recommendation for the treatment of HIV-MCD. In this retrospective (1998-2010), multicentric analysis of 52 histologically proven cases, outcome was analyzed with respect to the use of different MCD therapies and potential prognostic factors. After a mean follow-up of 2.26 years, 19 of 52 patients died. Median estimated overall survival (OS) was 6.2 years. Potential risk factors, such as older age, previous AIDS, or lower CD4 T cells had no impact on OS. Treatment was heterogeneous, consisting of cytostatic and/or antiviral agents, rituximab, or combinations of these modalities. There were marked differences in the outcome when patients were grouped according to MCD treatment. Patients receiving rituximab-based regimens had higher complete remission rates than patients receiving chemotherapy only. The mean estimated OS in patients receiving rituximab alone or in combination with cytostatic agents was not reached, compared with 5.1 years (P = .03). Clinical outcome and overall survival of HIV-MCD have markedly improved with rituximab-based therapies, considering rituximab-based therapies (with or without cytostatic agents) to be among the preferred first-line options in patients with HIV-MCD. (Blood. 2011;118(13):3499-3503)

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Hoffmann, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmid, HolgerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mueller, MarkusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Teutsch, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
van Lunzen, JanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Esser, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wolf, TimoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wyen, ChristophUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sabranski, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Horst, Heinz-AugustUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Reuter, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vogel, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jaeger, HansUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bogner, JohannesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Arasteh, KeikawusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-488772
DOI: 10.1182/blood-2011-02-333633
Journal or Publication Title: Blood
Volume: 118
Number: 13
Page Range: S. 3499 - 3504
Date: 2011
Publisher: AMER SOC HEMATOLOGY
Place of Publication: WASHINGTON
ISSN: 1528-0020
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ANTI-CD20 MONOCLONAL-ANTIBODY; ACTIVE ANTIRETROVIRAL THERAPY; INFECTED PATIENTS; FAILURE; VALGANCICLOVIR; INTERLEUKIN-6; SUPPRESSION; REMISSION; CYTOKINE; TRIALMultiple languages
HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/48877

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item